Fortress Biotech (FBIO) to Release Quarterly Earnings on Thursday

Fortress Biotech (NASDAQ:FBIO) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $16.30 million for the quarter.

Fortress Biotech Stock Performance

Shares of FBIO stock opened at $1.75 on Wednesday. The firm has a market cap of $48.31 million, a P/E ratio of -0.57 and a beta of 1.75. The business’s 50 day moving average price is $1.72 and its 200-day moving average price is $1.78. Fortress Biotech has a fifty-two week low of $1.36 and a fifty-two week high of $2.89.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm reissued a “buy” rating and set a $16.00 price target (up from $15.00) on shares of Fortress Biotech in a research report on Tuesday, March 11th.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.